	US 12,133,878 B2
	Pharmaceutical compositions having a selected release duration
Yuhua Li, Newark, DE (US); and Andrew J. Guarino, Newark, DE (US)
Assigned to Foresee Pharmaceuticals Co., Ltd., Taipei (TW)
Filed by Foresee Pharmaceuticals Co., Ltd., Taipei (TW)
Filed on Jun. 8, 2023, as Appl. No. 18/331,741.
Application 18/331,741 is a continuation of application No. 16/954,984, granted, now 11,717,555, previously published as PCT/US2017/066968, filed on Dec. 18, 2017.
Prior Publication US 2023/0346877 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/09 (2006.01); A61K 9/00 (2006.01); A61K 47/22 (2006.01); A61K 47/34 (2017.01)

CPC A61K 38/09 (2013.01) [A61K 9/0024 (2013.01); A61K 47/22 (2013.01); A61K 47/34 (2013.01)]

12 Claims

1. A pharmaceutical composition having a selected release duration comprising:

a) a combination of a strong acid salt and a weak acid salt of a luteinizing hormone releasing hormone (LHRH) agonist selected from the group consisting of leuprolide, triptorelin, and goserelin, wherein the molar ratio of (strong acid salt anion+weak acid salt anion) to the LHRH agonist is ≤2:1 and the molar ratio of the strong acid salt anion to the LHRH agonist is from 1:1 to less than 2:1;

b) a biodegradable polymer selected from the group consisting of a homopolymer polylactic acid (PLA) and a copolymer poly (lactic acid-co-glycolic acid) (PLGA), wherein the ratio of lactic acid:glycolic acid of the copolymer is from 50:50 to 100:0; and

c) N-methyl-2-pyrrolidone (NMP),

wherein the strong acid is methanesulfonic acid, and the weak acid is acetic acid or formic acid.